Hostname: page-component-76fb5796d-qxdb6 Total loading time: 0 Render date: 2024-04-26T15:34:26.327Z Has data issue: false hasContentIssue false
  • English
  • Français

X-ray powder diffraction data for olmesartan medoxomil, C29H30N6O6

Published online by Cambridge University Press:  17 February 2016

Xiaochun Chen ,
Peixiao Tang ,
Shanshan Li ,
Kailin Xu  and
Hui Li
Xiaochun Chen
Affiliation:
Research Center of Analytical Instrumentation, Key laboratory of Bio-resource and Eco-environment, Ministry of Education, College of Life Science, Sichuan University, Chengdu 610064, China
Peixiao Tang
Affiliation:
College of Chemical Engineering, Sichuan University, Chengdu, Sichuan 610065, China
Shanshan Li
Affiliation:
College of Chemical Engineering, Sichuan University, Chengdu, Sichuan 610065, China
Kailin Xu
Affiliation:
College of Chemical Engineering, Sichuan University, Chengdu, Sichuan 610065, China
Hui Li*
Affiliation:
College of Chemical Engineering, Sichuan University, Chengdu, Sichuan 610065, China
*
a)Author to whom correspondence should be addressed. Electronic mail: lihuilab@sina.com
Get access Rights & Permissions [Opens in a new window]

Abstract

X-ray powder diffraction data, unit-cell parameters, and space group for olmesartan medoxomil, C29H30N6O6, are reported [a = 12.3969(7) Å, b = 21.2667(3) Å, c = 10.9603(5) Å, α = γ = 90°, β = 101.38(9)°, unit-cell volume V = 2832.72 Å3, Z = 4 and space group P21/c]. All measured lines were indexed and are consistent with the P21/c space group. No detectable impurities were observed.

Keywords

X-ray powder diffractionolmesartan medoxomil
Type
Data Reports
Information
Powder Diffraction , Volume 31 , Issue 1 , March 2016 , pp. 73 - 76
Copyright
Copyright © International Centre for Diffraction Data 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Engel, G. E., Wilke, S., König, O., Harris, K. D. M., and Leusen, F. J. J. (1999). “Powder solve – a complete package for crystal structure solution from powder diffraction patterns,” J. Appl. Crystallogr. 32, 1169–1179.CrossRefGoogle Scholar
Hiroaki, Y., Yoshiya, A., Takuro, K., Yasuo, S., Koichi, F., Yoshiko, K., Toshio, S., Makoto, M., Masahiro, I., Shuichi, M., Youji, F., and Hiroyuki, K. (1996). “Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds,” J. Med. Chem. 39, 323–338.Google Scholar
Makoto, M., Toshio, S., Masahiro, I., Norio, F., Masaaki, M., Hiroaki, Y., and Hiroyuki, K. (1995). “Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist,” Eur. J. Pharmacol. 285, 181–188.Google Scholar
Richard, B., Eric, H., Thomas, G., Alaloor, S. D., Hemmige, S. Y., and Thomas, S. (2013). “Redetermination of the structure of olmesartan medoxomil, (5-methyl-2-oxo-2H-1,3-dioxol-4-yl)-methyl-4-(2-hydroxypropan-2-yl)-2-propyl-1-(-[2-(2H-1,2,3,4-tetrazol-5-yl)-phenyl]phenylmethyl)-1H-imidazole-5-carboxylate, C29H30N6O6 ,” Z. Kristallogr. NCS 228, 141–143.Google Scholar
Smith, D. H., Dubiel, R., and Jones, M. (2005). “Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy,” Am. J. Cardiovasc. Drug 5, 41–50.CrossRefGoogle ScholarPubMed
Xu, K. L., Liang, B., Wu, X. Q., Zhang, L. L., Tang, P. X., and Li, H. (2014). “X-ray powder diffraction data for levetiracetam,” Powder Diffr. 29, 51–52.CrossRefGoogle Scholar
Zhang, L. L., Pan, Q. Q., Xiao, D., Wu, X. Q., Wang, Q., and Li, H. (2013). “X-ray powder diffraction data for deoxyschisandrin,” Powder Diffr. 28, 231–233.CrossRefGoogle Scholar
Supplementary material: File

Chen supplementary material

Chen supplementary material 1

Download Chen supplementary material(File)
File 43.2 KB